156496-89-8

Basic information

• Product Name: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate;1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-3-oxo-, 1,1-diMethylethyl ester;tert-butyl 3-oxo-1,2,3,6-tetrahydropyridine-1-carboxylate;tert-Butyl 3-oxo-3,6-dihydropyridine-1(2H)-carboxylate;tert-Butyl 3-oxo-2,6-dihydropyridine-1-carboxylate
• CAS NO: 156496-89-8
• Molecular Formula: C₁₀H₁₅NO₃
• Molecular Weight: 197.231
• Mol File: 156496-89-8.mol

Chemical Properties

• Boiling Point: 299.2±39.0 °C(Predicted)
• Appearance: /
• Density: 1.130±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.95±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(156496-89-8)
• EPA Substance Registry System: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(156496-89-8)

Safety Data

• Hazardous Substances Data: 156496-89-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate is used as a reagent for the preparation of ω-alkoxy enones and α-amino enones from unsaturated alcohols or unsaturated amines. The compound serves as a key intermediate in the synthesis of these enones, which are valuable building blocks in organic chemistry and have various applications in the pharmaceutical and chemical industries.
The process involves the formation of intermediate phosphoranes, which are then subjected to ring-closing metathesis to yield the desired enones. This method provides a convenient and efficient route to synthesize a range of enone derivatives with potential applications in the development of new drugs, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate may be used as a starting material or intermediate for the synthesis of various drug candidates. The compound's unique structure and reactivity make it a promising candidate for the development of new therapeutic agents, particularly those targeting cardiovascular diseases, as dihydropyridines are known for their calcium channel-blocking properties.
Additionally, the compound's versatility in chemical synthesis allows for the exploration of its potential in the development of other therapeutic areas, such as anti-inflammatory, anti-cancer, and anti-infective agents.
Used in Material Science:
In the field of material science, tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate may find applications in the development of novel materials with specific properties. For instance, the compound could be used as a building block in the synthesis of new polymers, dyes, or sensors, taking advantage of its unique chemical structure and reactivity.

Upstream product

• 120568-74-3 N-allyl-N-(2-hydroxy-3-butenyl)amine 
• 224779-26-4 N-allyl-N-(2-hydroxy-but-3-enyl)-carbamic acid tert-butyl ester 
• 942056-42-0 tert-butyl allyl[2-oxo-3-(triphenyl-λ⁵-phosphoranylidene)prop-1-yl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161157-50-2 tert-butyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 691-64-5 di-tert-butyl oxalate 
• 224779-27-5 tert-butyl 3-hydroxy-1,2,3,6-tetrahydropyridine-N-carboxylate 

Downstream Products

• 156496-90-1 3-(2,6-Dichloro-phenyl)-4-oxo-4,5,7,7a-tetrahydro-3aH-isoxazolo[5,4-c]pyridine-6-carboxylic acid tert-butyl ester 
• 1268716-52-4 1-(4-bromo-benzyl)-5-(2-methyl-1H-indol-3-yl)-piperidin-3-one 
• 1373492-32-0 (2-chlorophenyl)-(3-oxo-3,6-dihydro-2H-pyridin-1-yl)acetic acid methyl ester 
• 1373492-33-1 (2-chlorophenyl)-(3-mercapto-5-oxopiperidin-1-yl)acetic acid methyl ester 
• 1373492-34-2 3-tert-butoxycarbonylmethylene-5-(mercaptopiperidin-1-yl)-(2-chlorophenyl)acetic acid methyl ester 
• 1373491-56-5 (3-carboxymethylene-5-mercaptopiperidin-1-yl)-(2-chlorophenyl)acetic acid methyl ester hydrochloride 

Relevant articles and documents

CHOLINE METABOLISM INHIBITORS

The present disclosure relates to compounds, compositions and methods for inhibiting choline metabolism, e.g., conversion of choline to trimethylamine. Disclosed herein are compounds, compositions, and methods for inhibiting choline metabolism, e.g., conversion of choline to TMA. Also disclosed herein are compounds, methods and compositions for inhibiting choline metabolism by gut microbiota resulting in reduction in the formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO).

Discovery of a Cyclic Choline Analog That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria

The anaerobic conversion of choline to trimethylamine (TMA) by the human gut microbiota has been linked to multiple human diseases. The potential impact of this microbial metabolic activity on host health has inspired multiple efforts to identify small molecule inhibitors. Here, we use information about the structure and mechanism of the bacterial enzyme choline TMA-lyase (CutC) to develop a cyclic choline analog that inhibits the conversion of choline to TMA in bacterial whole cells and in a complex gut microbial community. In vitro biochemical assays and a crystal structure suggest that this analog is a competitive, mechanism-based inhibitor. This work demonstrates the utility of structure-based design to access inhibitors of radical enzymes from the human gut microbiota.

DIPEPTIDE PIPERIDINE DERIVATIVES

The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.

INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted cyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Preparation of Z-α,β-unsaturated diazoketones from aldehydes. Application in the construction of substituted dihydropyridin-3-ones

The stereoselective preparation of α,β-unsaturated diazoketones with Z geometry is described from aldehydes and a new olefination reagent. When prepared from amino aldehydes, these diazoketones could be converted to substituted dihydropyridin-3-ones in just one step, after an intramolecular N-H insertion reaction. The straightforward synthesis of a natural trihydroxylated piperidine demonstrates the utility of these unsaturated diazoketones for the rapid construction of piperidines.

HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES

The present teachings relate to compounds of Formula I and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, ring A, and ( formula II) are as defined herein. The present teachin

COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION

The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.

Hydroxamate-Based Inhibitors of Deacetylases

The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, ring A, and are as defined herein. The present teachings also provi